Posted by Michael Wonder on 21 Nov 2018
ImmunoMolecular Therapeutics awarded SBIR grant and receives rare paediatric disease designation from FDA for IMT-002
14 November 2018 - Rare paediatric disease designation granted to IMT-002 for type 1 diabetes.
ImmunoMolecular Therapeutics today announced that it has been awarded a grant from the Small Business Innovation Research program to develop the D enantiomer of methyldopa (D-MDOPA) into an oral small molecule drug for the preservation of residual beta cell function in type 1 diabetes.
ImmunoMolecular Therapeutics is developing D-MDOPA as lead candidate, IMT-002, which was granted rare paediatric disease designation from the United States FDA.
